Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: nepafenac

« Back to Dashboard

Summary for Generic Name: nepafenac

Tradenames:2
Patents:6
Applicants:2
NDAs:2
Drug Master File Entries: see list3
Suppliers: see list2
Therapeutic Class:Ophthalmic Agents

Pharmacology for Ingredient: nepafenac

Clinical Trials for: nepafenac

Nepafenac 0.3% Two Study
Status: Completed Condition: Cataract

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Status: Active, not recruiting Condition: Diabetic Macular Edema

Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation
Status: Recruiting Condition: Macular Thickening; Macular Edema

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Status: Completed Condition: Intraocular Pressure

Confirmatory Study Nepafenac 0.3%
Status: Completed Condition: Cataract

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Status: Completed Condition: Inflammation; Pseudophakia

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Status: Recruiting Condition: Cataract; Retinal Edema; Inflammation

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
Status: Completed Condition: Intraocular Pressure

Nepafenac Once Daily for Macular Edema - Study 1
Status: Recruiting Condition: Non-Proliferative Diabetic Retinopathy; Cataract

Nepafenac Once Daily for Macular Edema - Study 2
Status: Recruiting Condition: Non-Proliferative Diabetic Retinopathy; Cataract

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes<disabled><disabled>
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862Aug 19, 2005RXYes8,324,281<disabled>Y<disabled>
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862Aug 19, 2005RXYes5,475,034<disabled><disabled>
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes7,947,295<disabled>Y<disabled>
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes5,475,034<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc